LinqMed Inc

LinqMed Inc. is a radiopharmaceutical startup focused on developing innovative visible anti-cancer treatments. The company, a certified venture of the National Institutes for Quantum Sciences and Technology (QST), utilizes proprietary technology centered on the copper radioisotope 64Cu. This isotope emits radiation for both diagnostic and therapeutic purposes, allowing the company to build a drug discovery platform designed to expedite the development of next-generation cancer therapies. By enabling precise, visible monitoring of treatment efficacy, the technology aims to create new infrastructure for the pharmaceutical industry.

These developments are significant for patients with intractable cancers, such as malignant brain tumors and pancreatic cancer, by potentially reducing unnecessary treatments and providing more personalized medical care. In collaboration with partners and through supported research initiatives, LinqMed works to establish large-scale 64Cu production and high-stability manufacturing technologies. The company’s efforts are geared toward solving critical economic and social challenges in oncology, with recent milestones including the completion of a factory in Chiba and successful fundraising rounds to support its growth and clinical research objectives.